> > Speaker Biographical Information

Malbika Sen

Title of talk: "Lung cancer epigenetics and therapeutics"

Title of talk:Summary of talk: Lung cancer is the leading cause of cancer deaths in the United States. Standard mode of therapy can involve a combination of surgery, chemotherapy, and radiation therapy. However, the general prognosis of lung cancer is poor as the disease is presented at an advanced stage because of the lack of early detection. This talk will discuss prevalence of aberrant promoter methylation as a crucial component in lung cancer initiation and progression and how gene promoter hypermethylation may be used as a target for developing therapeutic strategies.

Short biosketch: Dr. Malabika Sen is a Research Assistant Professor in the Department of Hematology/Oncology at the University of Pittsburgh Cancer Institute. Dr Sen's research focuses on cancer biology and therapeutics and has worked in many areas of cancer such as prostate, head and neck and more recently trying to understand and characterize epigenetic changes and development of therapeutic strategies based upon epigenetic alterations in lung cancer. Dr. Sen received her PhD degree in Biochemistry from India and came to University of Nebraska Medical Center in the Department of Ophthalmology, for her post doc. She then joined Department of Urology at the University of Pittsburgh Medical Center, as a Research Associate where she studied the role and metabolic pathway of fatty acids in prostate cancer. She then moved on to work in the area of head and neck cancer as a Research Associate, and then got promoted to Research Instructor and then to Research Assistant Professor, where her research focused on identifying new therapeutic strategies to target molecules that are upregulated in head and neck cancer. Currently her research focusses on studying and characterizing epigenetic changes of novel molecules and development of therapeutic strategies to target molecules based upon epigenetic alterations in lung cancer. She has 39 publications in high impact journals and has presented her work in many International meetings. She has been a member of the American Association for Cancer Research since 2005.